Australia markets open in 6 hours 40 minutes

GSK plc (GSK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
39.60-0.35 (-0.89%)
As of 01:19PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close39.95
Bid39.52 x 900
Ask39.53 x 800
Day's range39.44 - 39.85
52-week range33.33 - 43.84
Avg. volume3,607,353
Market cap82.938B
Beta (5Y monthly)0.27
PE ratio (TTM)13.24
EPS (TTM)2.99
Earnings dateN/A
Forward dividend & yield1.47 (3.67%)
Ex-dividend date22 Feb 2024
1y target est44.10
  • Insider Monkey

    10 Best Weight Loss Drug Stocks to Buy Now

    In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

  • Zacks

    GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

    Recently, users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

  • Reuters

    UPDATE 1-U.S. FDA approves Akebia's anemia drug

    The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.